Seismic Therapeutic Doses First Cohort in Phase 1 Clinical Trial of S‑1117, a Novel Pan‑IgG Protease Therapy for Antibody-Mediated Diseases
Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject ...
LabOnline9d
Proteintech FcZero recombinant antibodies for flow cytometry
Proteintech has designed recombinant antibodies featuring the company's FcZero backbone, engineered to silence the Fc domain ...
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...
Bosterbio’S ACAA2 Antibody Leads The Way In Advancing Cutting-Edge Research
Complementing its antibody offerings, BosterBio provides a range of ELISA kits designed for quantitative detection of ...